PCA
OPRX icon

Prospect Capital Advisors’s OptimizeRx OPRX Stock Holding History

Prospect Capital Advisors’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-46,100
Closed -$2.86M – 31
2021
Q4 		$2.86M Sell
46,100
-196,450
-81% -$14.9M 1.13% 23
2021
Q3 		$20.8M Sell
242,550
-64,600
-21% -$4.05M 6.85% 5
2021
Q2 		$19M Buy
+307,150
New +$15.6M 7.08% 5

Other funds holding OPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

Prospect Capital Advisors's OPRX Position: Q1 2022 in Review

Prospect Capital Advisors sold out of OptimizeRx (OPRX) in Q1 2022, closing a stake of 46,100 shares — an estimated $2.86M sold.

Prospect Capital Advisors first reported a position in OPRX in Q2 2021 and held it in 3 quarters. The position peaked at $20.8M in Q3 2021. 153 funds tracked by Wall St. Rank hold OPRX as of Q1 2022.

  • Prospect Capital Advisors reported no remaining OptimizeRx position as of Q1 2022 after selling out during the quarter.
  • Prospect Capital Advisors sold 46,100 OptimizeRx shares in Q1 2022, an estimated $2.86M.
  • Prospect Capital Advisors first reported a position in OptimizeRx in Q2 2021 and held it in 3 quarters.
  • Prospect Capital Advisors's OptimizeRx position peaked at $20.8M in Q3 2021.
  • 153 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2022.

Based on Prospect Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.